v3.26.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Apr. 30, 2026
Apr. 30, 2025
Operating activities    
Consolidated net loss $ (19,022) $ (18,589)
Adjustments to reconcile consolidated net loss to net cash used in operating activities    
Depreciation and amortization 153 238
(Gain) loss on sale of property and equipment (54) 81
Gain on settlement of accounts payable and convertible notes payable (3,958)
Realized gain on available-for-sale securities (178)
Amortization of discount on available-for-sale securities (285)
Loss on impairment of goodwill 3,050
Unrealized loss on equity investments - Cyclo 5,144
Unrealized loss on Convertible Notes, due from Cyclo 719
Stock-based compensation 1,157 1,214
Gain on DTLM Sale Transactions (30)
Change in assets and liabilities, net of effects from acquisitions:    
Trade accounts receivable 333 62
Interest receivable 515
Inventory 5 (18)
Prepaid expenses and other current assets (86) 1,023
Prepaid clinical trial costs (current and non-current) (719) (1,260)
Other receivables 1,206
Other assets (46) 21
Accounts payable and accrued expenses (176) (624)
Other current liabilities 4 (40)
Due to related parties (8) (69)
Accrued expenses, noncurrent (412) 463
Convertible notes payable 10 3
Other liabilities 13
Net cash used in operating activities (21,613) (8,547)
Investing activities    
Purchase of property and equipment (5) (5)
Proceeds from sale of property and equipment 76 13
Purchases of available-for-sale securities (16,894)
Purchase of preferred shares and warrants from Nina Medical (750)
Proceeds from the sale and maturities of available-for-sale securities 80,694
Purchase of intangible assets (17)
Issuance of Convertible Notes, due from Cyclo (19,500)
Cash paid in Cyclo Merger, net of cash acquired (2,709)
Proceeds from hedge funds 2,290
Net cash (used in) provided by investing activities (679) 43,872
Financing activities    
Payments for taxes related to shares withheld for employee taxes (79) (108)
Proceeds from sale of Rafael Medical Devices membership units 44
Cash paid to settle convertible notes payable (11)
Net cash used in financing activities (90) (64)
Effect of exchange rate changes on cash and cash equivalents 110
Net (decrease) increase in cash and cash equivalents (22,272) 35,261
Cash and cash equivalents, beginning of period 52,769 2,675
Cash and cash equivalents, end of period 30,497 37,936
Non-cash supplemental disclosure    
Fair value of Class B common stock issued as consideration in Cyclo Merger 14,692
Fair value of Rollover Options issued as consideration in Cyclo Merger 360
Fair value of Replacement Warrants issued as consideration in Cyclo Merger 472
Fair value of Cyclo Convertible notes receivable included as consideration in Cyclo Merger 21,472
Withdrawal receivable from Hedge Funds included in other current assets 257
Convertible note receivable received in exchange for Day Three Labs Manufacturing assets $ 500